Indications for Intravenous Ceftriaxone
Intravenous ceftriaxone is indicated for serious bacterial infections including meningitis, sepsis, pneumonia, complicated urinary tract infections, gonorrhea, pelvic inflammatory disease, skin/soft tissue infections, bone/joint infections, and intra-abdominal infections caused by susceptible organisms.
Primary Indications by Clinical Setting
Central Nervous System Infections
Bacterial Meningitis is a critical indication where ceftriaxone demonstrates excellent CSF penetration:
- Adults: 2 g IV every 12 hours for meningococcal disease (5 days if recovered), pneumococcal disease (10-14 days), H. influenzae (10 days), or Enterobacteriaceae (21 days) 1
- Pediatrics:
- Infants 8-28 days: Use ampicillin plus ceftazidime instead (ceftriaxone avoided due to bilirubin displacement risk) 2
- Infants 29-60 days and children: 100 mg/kg/day IV (max 4 g) once daily or divided every 12 hours 2, 3
- Recent evidence supports once-daily dosing achieving superior CSF target attainment compared to twice-daily regimens 4
Febrile Illness in Infants
For well-appearing febrile infants 22-60 days old with suspected bacteremia or UTI without identified focus, ceftriaxone 50 mg/kg IV/IM once daily is recommended 2. This can be administered as outpatient therapy with close follow-up.
Respiratory Tract Infections
Community-Acquired Pneumonia requiring hospitalization:
- Standard dosing: 1-2 g IV once daily in adults 3
- Recent comparative data shows 1 g daily is non-inferior to 2 g daily for mortality in non-critically ill patients with similar or lower adverse event rates 5, 6
- Severe pneumonia requiring mechanical ventilation: 2 g daily associated with lower mortality 5
- Combination with macrolide coverage is standard for atypical pathogens 6
Genitourinary Infections
Uncomplicated gonorrhea: Single IM dose of 250 mg (adults) or 125 mg (children <45 kg) 7, 8, 3
Complicated UTI/Pyelonephritis: 50 mg/kg once daily in infants >28 days; 1-2 g daily in adults 2, 3
Pelvic inflammatory disease: Standard adult dosing, but must add appropriate antichlamydial coverage as ceftriaxone has no activity against Chlamydia trachomatis 3
Sepsis and Bacteremia
- Infants 22-60 days: 50 mg/kg IV/IM once daily 2
- Adults: 1-2 g IV once or twice daily depending on severity 3
- Effective against S. aureus, S. pneumoniae, E. coli, H. influenzae, K. pneumoniae 3
Skin, Soft Tissue, Bone and Joint Infections
Pediatric patients: 50-75 mg/kg once daily (max 2 g) 3
Adults: 1-2 g once or twice daily 3
Duration typically 7-14 days, but bone/joint infections may require longer courses 3
Other Specific Indications
Acute bacterial sinusitis (severe cases): Can use IM/IV ceftriaxone 50 mg/kg once for children unable to tolerate oral therapy, then transition to oral antibiotics 7
Acute otitis media (treatment failure): Single IM dose of 50 mg/kg (max 1 g) for children with persistent symptoms 2, 3
Surgical prophylaxis: Single 1 g IV dose 30 minutes to 2 hours preoperatively 3
Critical Dosing Considerations
Age-Specific Restrictions
Neonates <7 days old: Ceftriaxone is generally avoided due to risk of bilirubin encephalopathy from displacement of bilirubin from albumin binding sites. When used, infuse over 60 minutes 3
Premature infants: Use with extreme caution; alternative agents preferred 2
Renal/Hepatic Impairment
No dosage adjustment required for renal or hepatic impairment alone, but monitor closely if both are severely impaired 3
Maximum Doses
Important Caveats and Pitfalls
Calcium-containing solutions: Never mix ceftriaxone with calcium-containing diluents (Ringer's, Hartmann's) due to precipitation risk 3
Drug incompatibilities: Do not mix with vancomycin, aminoglycosides, fluconazole, or amsacrine in same IV line; flush thoroughly between administrations 3
Resistance patterns:
- Ceftriaxone has no activity against MRSA, Listeria monocytogenes, or Chlamydia trachomatis 1, 3
- Increasing ESBL-producing Enterobacteriaceae may require meropenem instead 1
- For S. pneumoniae with ceftriaxone MIC >0.5 mg/L, add vancomycin or rifampicin 1
Biliary complications: Reversible biliary pseudolithiasis can occur, especially with doses ≥2 g/day, though true lithiasis incidence is <0.1% 9
Meningococcal carriage: Ceftriaxone uniquely eradicates nasopharyngeal carriage; patients treated with other beta-lactams for meningococcal disease need additional ciprofloxacin 500 mg PO once for prophylaxis 1